Friday, May 3, 2013

Pfizer Initiates Inflximab biosimilar bioequivalence Phase 1 trial

Pfizer has inititated a bioequivalence trial comparing its biosimilar infliximab (PF-06438179)
to Merck/ JNJ's Remicade (Infliximab). The trial will enroll 129 candidates and will complete in September 2013. There are two active comparator arms involving infliximab (European Union) and Infliximab (US)

Enter your email address:


Delivered by FeedBurner